G. Walmsley Graham - Sep 19, 2022 Form 4/A - Amendment Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Director
Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Sep 19, 2022
Transactions value $
$15,440,000
Form type
4/A - Amendment
Date filed
6/15/2023, 09:26 PM
Date Of Original Report
May 23, 2023
Previous filing
Jun 27, 2022
Next filing
Jun 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Purchase $10.4M +400K $26.00 400K Sep 19, 2022 See Footnote F1, F2
transaction AKRO Common Stock Purchase $5.04M +120K +30% $42.00 520K May 19, 2023 See Footnote F2
holding AKRO Common Stock 2.17K Sep 19, 2022 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Form 4 amendment is being filed solely to correct the original Form 4 filed on May 23, 2023, which inadvertently included the incorrect transaction date of September 19, 2023, due to a clerical error. This amendment corrects the date of the transaction to September 19, 2022.
F2 The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.